Search

Your search keyword '"Terryn, Wim"' showing total 31 results

Search Constraints

Start Over You searched for: Author "Terryn, Wim" Remove constraint Author: "Terryn, Wim" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
31 results on '"Terryn, Wim"'

Search Results

1. Loss of phospholipase PLAAT3 causes a mixed lipodystrophic and neurological syndrome due to impaired PPARγ signaling

2. Shortcutting the diagnostic odyssey: the multidisciplinary Program for Undiagnosed Rare Diseases in adults (UD-PrOZA)

3. Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

4. Campylobacter coli Prosthetic Joint Infection: Case Report and a Review of the Literature.

5. IRF2BPL Is Associated with Neurological Phenotypes

7. Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with Covid-19: an open-label randomized controlled trial

8. Additional file 2 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

9. Additional file 2 of Shortcutting the diagnostic odyssey: the multidisciplinary Program for Undiagnosed Rare Diseases in adults (UD-PrOZA)

10. Additional file 6 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

11. Additional file 1 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

12. Additional file 5 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

13. Additional file 4 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

14. Additional file 7 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

15. Additional file 1 of Shortcutting the diagnostic odyssey: the multidisciplinary Program for Undiagnosed Rare Diseases in adults (UD-PrOZA)

16. Additional file 3 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

17. Screening for Fabry Disease in Male Patients With Arrhythmia Requiring a Pacemaker or an Implantable Cardioverter-Defibrillator

18. Mutations in RNU7-1 Weaken Secondary RNA Structure, Induce MCP-1 and CXCL10 in CSF, and Result in Aicardi-Goutières Syndrome with Severe End-Organ Involvement.

19. Screening for Fabry Disease in Male Patients With Arrhythmia Requiring a Pacemaker or an Implantable Cardioverter–Defibrillator

23. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

25. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease:the European Fabry Working Group consensus document

27. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document

28. Late onset ornithine transcarbamylase deficiency in a 61 year old male

29. Chronic kidney disease and an uncertain diagnosis of Fabry disease: Approach to a correct diagnosis

30. Aggressive extensive cardiac mass in an HIV-1-infected patient: should we go for comfort therapy?

31. Intermediate uveitis in common variable immunodeficiency (CVID) associated with a heterozygous variant in the TNFRSF13B gene.

Catalog

Books, media, physical & digital resources